Literature DB >> 7672747

[Bromelain in blunt injuries of the locomotor system. A study of observed applications in general practice].

M Masson.   

Abstract

METHOD: In an open case observation study involving patients with blunt injuries to the musculoskeletal system, the efficacy and tolerability of high-dose Bromelain POS, a plant-derived enzyme preparation, were investigated. The investigating physician was an orthopedic surgeon who, in addition to the usual therapeutic measures, treated 59 of his patients with the bromelaine preparation. The duration of the application was determined by the nature and severity of the lesion, and varied between one and three weeks. The test criteria were swelling, pain at rest and during movement, and tenderness. These parameters were evaluated on the day of the injury and on five subsequent dates.
RESULTS: Treatment with bromelaine resulted in a clear reduction in all four parameters tested. Both swelling and the symptoms of pain had improved appreciably at all evaluation time points as compared with baseline. The tolerability of the preparation was very good, and patient compliance was correspondingly high.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7672747

Source DB:  PubMed          Journal:  Fortschr Med        ISSN: 0015-8178


  4 in total

1.  Bromelain treatment decreases secretion of pro-inflammatory cytokines and chemokines by colon biopsies in vitro.

Authors:  Jane E Onken; Paula K Greer; Brian Calingaert; Laura P Hale
Journal:  Clin Immunol       Date:  2007-12-21       Impact factor: 3.969

2.  Bromelain treatment decreases neutrophil migration to sites of inflammation.

Authors:  David J Fitzhugh; Siqing Shan; Mark W Dewhirst; Laura P Hale
Journal:  Clin Immunol       Date:  2008-05-14       Impact factor: 3.969

3.  Case report: comprehensive management of medial tibial stress syndrome.

Authors:  Bernard John Krenner
Journal:  J Chiropr Med       Date:  2002

4.  Plant proteolytic enzyme papain abrogates angiogenic activation of human umbilical vein endothelial cells (HUVEC) in vitro.

Authors:  Thomas Mohr; Lucia Desser
Journal:  BMC Complement Altern Med       Date:  2013-09-21       Impact factor: 3.659

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.